Market Cap: $49.28B
Market Cap: $49.28B
Open
$34.99
Prev. Close
$42.62
High
$35.47
Low
$34.58
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams.
Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange under the ticker TEVA, priced in USD.
Teva Pharmaceutical Industries Limited has a market capitalisation of $49.28B, based on its latest share price.
TEVA trades at 94.23 times its trailing 12-month earnings.
Over the past 52 weeks TEVA has traded between $14.99 and $44.57.
No. Teva Pharmaceutical Industries Limited does not currently pay a dividend.
Profitable, with a net margin of 2.9% over the last 12 months.
The analyst consensus rating for TEVA is Buy.
Richard D. Francis is the CEO of Teva Pharmaceutical Industries Limited, which is headquartered in Tel Aviv.
Generated automatically from reported financial data. General information only, not financial advice.

Teva Pharmaceutical Industries Limited ( TEVA ) is undergoing a transformative phase that marks a significant departure from its previous struggles in the generic drugs market. With a strategic pivot…

Teva Pharmaceutical Industries (Ticker: TEVA) makes headlines with its recent filing for ecopipam, a groundbreaking treatment for pediatric Tourette syndrome. This New Drug Application (NDA) has been…

Teva Pharmaceutical Industries (Ticker: TEVA) embarks on a significant advancement in its product offerings with the launch of AHZANTIVE, a novel biosimilar designed for the treatment of retinal condi…

Teva Pharmaceutical Industries (Ticker: TEVA) announces important findings from its IMPACT-TD Registry that spans three years, focusing on tardive dyskinesia (TD). This research is particularly releva…